{"pub": "axios", "url": "https://axios.com/lipitor-pfizer-drug-patent-sales-2019-6937cdfb-47f1-46bc-8cf0-39e6b88e235e.html", "downloaded_at": "2019-10-30 09:24:35.789823+00:00", "title": "Cholesterol drug Lipitor is still generating billions for Pfizer", "language": "en", "text": "Data: Company filings; Note: First nine months of 2019 shown; Chart: Naema Ahmed/Axios\n\nLipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago.\n\nThe big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic competitors that cost pennies per pill, shows how distorted the global pharmaceutical system can be.", "description": "Lipitor's patent expired in 2011.", "authors": [], "top_image": "https://images.axios.com/d77fYhyE1kVbEbAoCz6SrncKsxw=/0x0:2400x1350/1920x1080/2019/10/29/1572388541340.png", "published_at": "2019-10-30"}